Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865500 | 0.89 | JAK2 (0.55) | JAK2CHEK1P2RX7POLB | |
| SCHEMBL2868890 | 0.87 | MAPT (0.48) | JAK2CHEK1MAPTPOLB | |
| SCHEMBL13930515 | 0.85 | JAK2 (0.44) | JAK2CHEK1MAPT | |
| SCHEMBL2863457 | 0.83 | JAK2 (0.43) | JAK2CHEK1MAPT | |
| SCHEMBL2868062 | 0.83 | JAK2 (0.42) | JAK2CHEK1MAPT | |
| SCHEMBL2870465 | 0.82 | JAK2 (0.42) | JAK2CHEK1MAPT | |
| SCHEMBL2867299 | 0.82 | JAK2 (0.53) | JAK2 | |
| SCHEMBL2863289 | 0.80 | JAK2 (0.55) | JAK2 | |
| SCHEMBL2865692 | 0.77 | JAK2 (0.46) | JAK2MAPTRXFP1CYP1A2CYP2C9 | |
| SCHEMBL2866648 | 0.77 | JAK2 (0.45) | JAK2CHEK1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | claimed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | claimed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | claimed |
| EP-2200612-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009035575-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | claimed |
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2200612-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009035575-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035575-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | JAK2 1/4885CHEK1 740/4885MAPT 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.